Arsenal Biosciences co-founder and CEO Ken Drazan, MD
Arsenal Biosciences co-founder and CEO Ken Drazan, MD

Programmable cell therapy company Arsenal Biosciences, which Westlake Village BioPartners seeded and significantly contributed to its Series A financing, today announced a $70 million multi-program discovery collaboration with Bristol Myers Squibb to advance next-generation T cell therapies for solid tumors.

For more information, please see this press release.